Shares of ImmunoGen Inc. blasted off toward a record rally in very-active trading Wednesday, after the biotechnology company said a late-stage trial of its treatment for ovarian cancer produced positive survival results.
The company said Elahere (mirvetuximab soravtansine-gynx) demonstrated in a Mirasol Phase 3 confirmatory trial a “significant and clinically meaningful” survival benefit in patients with platinum-resistant ovarian cancer who have received one to three prior lines of therapy. Patients also demonstrated progression-free…
Read the full article here